Close Menu

NEW YORK – Precision medicine firm Genetron Health and Chia Tai Tianqing Pharmaceutical Group have entered an exclusive strategic partnership to exclusively  comarket and copromote Genetron's HCCscreen – a blood-based early screening test for liver cancer — in hospitals across designated territories in China.

The parties intend to target high-risk individuals for hepatocellular carcinoma, which include hepatitis B virus carriers, as well as other liver disease patients, using CTTQ's experienced sales force and hospital relationships.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.